Acromegaly - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 91
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A501AB72FA4EN
Leaflet:

Download PDF Leaflet

Acromegaly - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Acromegaly - Pipeline Review, H2 2016’, provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Acromegaly
  • The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
  • The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acromegaly
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acromegaly
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acromegaly Overview
Therapeutics Development
Pipeline Products for Acromegaly - Overview
Pipeline Products for Acromegaly - Comparative Analysis
Acromegaly - Therapeutics under Development by Companies
Acromegaly - Therapeutics under Investigation by Universities/Institutes
Acromegaly - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acromegaly - Products under Development by Companies
Acromegaly - Products under Investigation by Universities/Institutes
Acromegaly - Companies Involved in Therapeutics Development
Aegis Therapeutics, LLC
Amryt Pharma plc
Antisense Therapeutics Limited
Chiasma, Inc.
Crinetics Pharmaceuticals, Inc.
DexTech Medical AB
Foresee Pharmaceuticals, LLC
Glide Pharmaceutical Technologies Limited
Ionis Pharmaceuticals, Inc.
Ipsen S.A.
Italfarmaco S.p.A.
Midatech Pharma Plc
Novartis AG
Peptron, Inc.
Strongbridge Biopharma plc
Sun Pharma Advanced Research Company Ltd.
Acromegaly - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COR-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-GHRLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITF-2984 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-779976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate long acting - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SXN-101959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Featured News & Press Releases
Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
Jul 13, 2016: ATL1103 Patent Update
Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
Apr 18, 2016: Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa New Drug Application
Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application
Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference
Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced
Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 91

LIST OF TABLES

Number of Products under Development for Acromegaly, H2 2016
Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2016
Acromegaly - Pipeline by Amryt Pharma plc, H2 2016
Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2016
Acromegaly - Pipeline by Chiasma, Inc., H2 2016
Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
Acromegaly - Pipeline by DexTech Medical AB, H2 2016
Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Acromegaly - Pipeline by Ipsen S.A., H2 2016
Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2016
Acromegaly - Pipeline by Midatech Pharma Plc, H2 2016
Acromegaly - Pipeline by Novartis AG, H2 2016
Acromegaly - Pipeline by Peptron, Inc., H2 2016
Acromegaly - Pipeline by Strongbridge Biopharma plc , H2 2016
Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acromegaly - Dormant Projects, H2 2016
Acromegaly - Discontinued Products, H2 2016 78

LIST OF FIGURES

Number of Products under Development for Acromegaly, H2 2016
Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Acromegaly - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 90 pages
Schistosomiasis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 39 pages
Xerostomia - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 41 pages
Pheochromocytoma - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 68 pages

Ask Your Question

Acromegaly - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: